Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,391 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Pill Clear all

Conditions: Epilepsy
Interventions: Memantine, Sugar Pill; Drug · Other
Lead sponsor: American Academy of Neurology; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • Newton, Massachusetts

Conditions: PTSD, Sleep Disorders
Interventions: prazosin, placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Loma Linda, California • Long Beach, California • Palo Alto, California + 12 more

Conditions: Melanoma, Metastatic Melanoma
Interventions: Ipilimumab, Nivolumab, Troriluzole, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Smoking Cessation, Electronic Cigarette Use
Interventions: Varenicline, Nicotine patch, Dual Focused Cessation Counseling, Smoking Focused Cessation Counseling, Counseling Intensity: 1 Session, Counseling Intensity: 4 Sessions; Drug · Behavioral · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Postural Tachycardia Syndrome
Interventions: Placebo oral tablet, Moxonidine Pill; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Opioid-use Disorder
Interventions: Take-home Dosing Procedures; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostatic Neoplasms
Interventions: HSV-tk with Valacyclovir & Brachytherapy; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atherosclerosis, Diabetes, Coronary Artery Disease
Interventions: Nicotinamide riboside (NR), Placebo; Dietary Supplement · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 39 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: mixed amphetamine salts-extended release (MAS-XR), Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 10 Years to 18 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension
Interventions: Slow sodium tablets, placebo; Drug · Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 50 Years to 79 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Core Body Temperature
Interventions: ELITE 3 HQ; Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
Interventions: Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo, Questionnaire Administration; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Evanston, Illinois • Rochester, Minnesota • Camden, New Jersey

Conditions: Dementia With Lewy Bodies
Interventions: Placebo Oral Tablet, Bosutinib Oral Tablet; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 25 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Eating Disorders, Hypoestrogenemia
Interventions: 17-β estradiol transdermal patches, Placebo Patch, Micronized progesterone 200 MG, Placebo Pill.; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 35 Years · Female only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aging
Interventions: Sirolimus; Drug
Lead sponsor: Irina Timofte; Other
Eligibility: 65 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type1 Diabetes
Interventions: HCL, verapamil 120mg tablet, non-HCL, placebo; Device · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more

Conditions: Depression
Interventions: L-tyrosine, L-Tryptophan, deplin, Placebo A, Placebo B; Dietary Supplement · Drug · Other
Lead sponsor: John D. Dingell VA Medical Center; Federal
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Chronic Hepatitis C
Interventions: SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir), Ribavirin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 1,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 38
States / cities: Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more

Conditions: Asthma
Interventions: Lansoprazole, Matching placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Bupivacaine, patient-reported pain scores, saline; Drug · Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Improving Cardiometabolic Outcomes in Older Adults
Interventions: Melatonin 1 mg, Placebos, Meal timing, Non-Meal timing; Dietary Supplement · Other
Lead sponsor: Northwestern University; Other
Eligibility: 55 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Hyposexual Desire Disorder
Interventions: Flibanserin Pill; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Norwalk, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more

Conditions: Chronic Fatigue Syndrome
Interventions: Hydrogen water; Dietary Supplement
Lead sponsor: Stony Brook University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stony Brook, New York

Search by objective public record fields.

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?

Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

The Avenues Study: Dual Use Cessation

Autonomic Determinants of POTS - Pilot 2

Evaluating a Novel Medication Device for Methadone Dosing

HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder

Efficacy of Dietary Sodium Restriction of Improving Vascular Endothelial Function in Middle Aged and Older Adults

Pill Study Hyperthermia Device (Heckel HT 3000): Monitoring Core Body Temperature Using Wireless Technology

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

The Role of Estrogen in the Neurobiology of Eating Disorders

The Role of Sirolimus in Preventing Functional Decline in Older Adults

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

Pilot Study: Combining Nutritional Supplements With Standard Antidepressant to Treat Depression.

Study of Oral Treatments for Hepatitis C

Lansoprazole to Treat Children With Asthma

Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia

Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

Aging Program Project Grant 6

A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors

Hydrogen Water Treatment for Chronic Fatigue Syndrome